Výsledky vyhledávání - "Alexia Suárez"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages

Autor: Alexia Suárez-Cabrera, Dolly Viviana Fiallo-Suárez, Ruth Stuckey, Marta Luna Uroz-de la Iglesia, Yanira Florido, Angelina Lemes-Castellano, Miguel Ángel Perera-Álvarez, Hugo Luzardo-Henríquez, Haridian de la Nuez, Paula Fernández-Caldas, Silvia de la Iglesia, María Teresa Gómez-Casares, Cristina Bilbao-Sieyro

Publikováno v: Diagnostics, Vol 12, Iss 8, p 1802 (2022)

Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly after diagnosis. In a consecutive series of 217 CLL patients, molecular biomarkers with pr

Externí odkaz: https://doaj.org/article/b2da8c5392ed45e3971b3b379f7afb1e

Zobrazit plný text záznamu

Akademický článek

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Publikováno v: HemaSphere, Vol 4, Iss 3, p e380 (2020)

Abstract. Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided ea

Externí odkaz: https://doaj.org/article/1672ec490b6f4daa88e72c748386ae98

Zobrazit plný text záznamu

Akademický článek

Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.

Publikováno v: Leukemia & Lymphoma; May2023, Vol. 64 Issue 5, p913-926, 14p

Zobrazit plný text záznamu

Plný text ve formátu HTML

Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

Publikováno v: LEUKEMIA & LYMPHOMA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460ca835ab8be37226e2b48f15b65c34
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13943

Zobrazit plný text záznamu

P-224: Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S158

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17aae1bda506ce109d6ddeb6b0ec3796
https://doi.org/10.1016/s2152-2650(22)00554-7

Zobrazit plný text záznamu

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Publikováno v: Blood. 138:76-76

Background: CTCs may be responsible for MM spreading and accordingly, their numbers in peripheral blood (PB) could be a potential surrogate marker for the rate of dissemination and overall tumor burden in bone marrow (BM). In such case, CTCs may be a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bfb7d03383d944dd96a0af5639d98ec
https://doi.org/10.1182/blood-2021-146535

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Autor: Jose M Arguiñano, Angeles Medina, Ana Lario, Santiago Osorio-Prendes, Javier Loscertales, Lucrecia Yáñez, Patricia Baltasar, Fernando De Marco, Julio Delgado, Margarita Fernández de la Mata, Macarena Ortiz Pareja, Miguel Ganuza Fernandez, Inmaculada Pérez, Alicia Rodríguez, Rafael Ramos, Ana Cristina Godoy, Ruben Fernandez, Alexia Suárez Cabrera, Jose Luis Bello, Jose Angel Hernandez-Rivas, Carmen Losada, Montserrat López Rubio, Aima Lancharro Anchel, María-Jesús Vidal, Eduardo Rios Herranz, Angel Ramirez Payer, Isidro Jarque, Ana Célia Carneiro Oliveira, Maria José Berruezo, Pau Abrisqueta Costa, Carolina Cuellar, Paloma Martin, María-Dolores García-Malo, Ernesto Pérez Persona, María José Terol, Cristina Loriente, Alicia Smucler Simonovich, Ricardo Francisco Garcia, Miguel Villanueva

Publikováno v: Blood. 136:32-33

Introduction. Ibrutinib is a first-in-class, oral, once-a-day Bruton's tyrosine kinase inhibitor that achieves high overall response rates and durable remissions in patients with chronic lymphocytic leukemia (CLL) including those with high-risk featu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d76bf26c288ba86c1684e5da66b1577d
https://doi.org/10.1182/blood-2020-136036

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání